What happened with BMRA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Biomerica makes test kits that analyze patient samples to detect substances associated with diseases and other medical conditions. Clinical laboratories account for most revenue; it also sells products through over-the-counter channels. A smaller business develops and manufactures diagnostic products for other companies. Under a development agreement with a life sciences company, it earns fees as agreed project milestones are completed and accepted.
Its inFoods IBS blood test identifies foods associated with a patient’s heightened immune response. Patients may then remove those foods from their diet to help manage irritable bowel syndrome symptoms. The product is still in early commercialization through physicians and laboratories. Medicare has established a payment rate, and initial valid claims from its partner laboratory have been paid, but this does not guarantee coverage or payment for every test.
A substantial share of sales comes from international markets through independent distributors. One distributor supplies a large share of revenue, and the company also depends significantly on its distribution partner in China. Sales in Europe, China and other markets require regulatory authorizations; evolving European diagnostic-testing rules may delay or limit sales of certain products.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BIOMERICA INC’s results hinge on international diagnostic-kit orders and contract-development milestones, while its emerging inFoods IBS opportunity depends on physician adoption and actual insurance coverage and payment.
Trinity Biotech plc shares Biomerica’s exposure to international diagnostic sales: both sell tests to clinical laboratories and point-of-care settings through distributors. Watch Trinity’s overseas laboratory-test sales and distributor news for clues about the channels Biomerica also relies on.
QuidelOrtho Corporation sells diagnostic tests to the same customer groups as Biomerica—clinical laboratories, physician offices and people buying tests over the counter—but its instrument-based business is much broader. Watch its point-of-care and over-the-counter products rather than treating its recurring revenue from instrument-linked tests and supplies as a direct comparison for Biomerica.
Anbio Biotechnology competes in Biomerica’s laboratory, point-of-care and over-the-counter markets, selling tests that analyze samples outside the body. Unlike Biomerica, which manufactures diagnostic products, Anbio hires outside laboratories to help develop its tests and outside suppliers to manufacture them, retaining the revenue and profits from product sales.
BIOMERICA INC earningsThis company
Biomerica's report will show whether clinical-laboratory orders and inFoods IBS sales can lift revenue enough to spread manufacturing costs across more products.
Read clinical-laboratory sales alongside gross margin, the share of sales left after product costs. Rising sales with an improving margin would show that more orders are helping absorb fixed manufacturing costs. Continued sales weakness with a margin still pressured by low volume would show that the business is not yet covering those costs well, leaving cash needs unresolved.
QuidelOrtho Corporation earningsQDEL
QuidelOrtho's report will show how its point-of-care and over-the-counter diagnostic products are selling in channels Biomerica also serves.
Focus on sales of QuidelOrtho's point-of-care and over-the-counter products, not its much broader instrument-linked recurring sales. Strength in those products would suggest demand is holding up in channels Biomerica also serves; weakness could signal softer demand or stronger competition for Biomerica's related tests.
Trinity Biotech plc earningsTRIB
Trinity Biotech's report will show whether overseas laboratory-test sales and distributor channels are holding up—channels Biomerica also relies on.
Watch Trinity Biotech's overseas laboratory-test sales alongside any distributor updates. Steady sales and functioning distributor channels would suggest the international route both companies use is holding up; weaker sales or distributor problems would point to possible pressure on Biomerica's overseas orders and shipments too.
